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 Use of monoclonal antibodies or fragments thereof as 
affinity elements for immunoFET construction 
- Anticipate improved consistency for charge detection 
and distance of charge from the sensing surface. 
- Increased sensitivity as result of reduced noise to 
signal ratio. 
 TEA (APTES type silane) vs. APDMES type silane as 
polymer film 
- TEA has shown to create a meshwork while APDMES 
type silane would provide a monolayer and highly 
ordered surface and thus 4x106 increase in 
sensitivity  
 
 
 
 
 
 
 
 Binding of CXCL9 to bring C-terminus (high density of 
positive charge) close to sensing surface to increase 
sensitivity 
 
 
 
 Figure 1. ImmunoFET device cross-section. Illustration of 
AlGaN/GaN heterojunction FET used.  
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Introduction 
ImmunoFET Device Layout 
ImmunoFET Selectivity 
CXCL9 Detection in Patient Urine 
Opportunities for Optimization 
Future Work 
• Continue testing in complex physiologic environments 
(transplant patient urine, serum), move into 
tissue/tissue homogenates, detection of additional 
proteins of interest 
• Working toward clinical device capable of real-time, 
label-free, point-of-care testing of protein levels in 
vivo 
Field effect transistors (FETs) are semiconductor devices 
that use electric fields to modulate current in a conductive 
channel. The application of an electric field proximal to 
the conductive channel causes either an increase or 
decrease in current depending on the sign and magnitude 
of the field. 
 FETs can be modified to allow protein sensing by 
deploying receptors on channel surface 
 FETs modified with immunological receptors (i.e. 
antibodies) are known as immunoFETs 
 Binding of proteins to receptors brings layer of 
charge proximal to channel surface and modulates 
current 
 Potential for real-time, label-free detection of 
proteins in physiologic buffers and in vivo 
 Tool for physicians to monitor critical protein levels 
Figure 5. CXCL9 detection in urine of renal transplant patients.  
Figure 6. FET Sensor Optimization.  
 2DEG is sensitive to changes in electric potential at 
AlGaN surface 
 Binding of positively charged proteins create a layer 
of charge and this electric field increases current in 
the device, while negatively charged proteins 
decrease current in the device 
 Distance between analyte and channel is important 
as sensitivity drops of to 6th power of distance due to 
counter-ion shielding 
Silicone Silicone 
AlGaN 
GaN 
Sapphire Substrate 
2DEG 
Micro 
Reservoir 
Ohmic 
Contact 
Ohmic 
Contact 
AlGaN 
=  Analyte 
=  Receptor 
=  Silane 
- - - - - + + + + + 
 In an immunoFET, the metal gate is removed and 
replaced by a layer of receptors  
 Reservoir is created with silicone rubber to allow liquid 
samples to be placed on device over the conducting 
channel 
 Receptors (antibodies) are attached to conducting 
channel via silane layer and bind analyte of interest. 
 The 2-dimensional electron gas (2DEG) created 
between AlGaN/GaN layers provides electrons for 
current flow 
 Current is modulated by electric field proximal to the 
AlGaN surface i.e. electrical charge of bound proteins 
cause a change in device current (Ids) 
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Figure 2. Basic function of immunoFET. This is for an N-
type FET where electrons are the charge carriers. 
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Figure 3. ImmunoFET specificity determined by receptor. Detection 
of huCXCL9 and muCXCL9 in PBS (pH 7.4). 
 ImmunoFET with receptors for human CXCL9 tested 
with protein samples of both human and murine CXCL9  
 Demonstrated that device signal is driven by 
receptor specificity and able to distinguish between 
exceedingly similar proteins 
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 Successful detection of 100ng/ml human CXCL9 in a 
complex physiologic buffer-murine serum 
Figure 4. ImmunoFET detection of huCXCL9 in murine serum.. 
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 Preliminary immunoFET testing results detecting 
CXCL9 in the urine of renal transplant patients 
 Samples from both patients undergoing acute rejection 
episodes and non-rejecting patients  
 Differential CXCL9 levels confirmed by ELISA, initially 
blinded to patient allograft status 
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Figure 7. Conceptual illustration of APTES (a) and APDMES (b). 
Figure 8. Secondary structure of CXCL9 with 1 depicting the first 
residue of the N-terminus [Cole, et. al. J Immunology 2001; 167: 
623-627] 
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ELISA Corroboration 
 ELISA performed to detect CXCL9 in the urine of renal 
transplant patients and related to rejection. 
 Samples from both patients undergoing acute rejection 
episodes and non-rejecting patients. 
 Initially blinded to patient allograft status. 
 From literature, CXCL9 levels of greater than 
~330pg/ml experience acute rejection.  
